Abstract
IntroductionWe provide long-term data on the effectiveness of Vedolizumab (VDZ) in the management of inflammatory bowel disease (IBD) by reviewing the response of surrogate markers of disease activity to VDZ...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
